-
Views
-
Cite
Cite
E. Mensà, R. Recchioni, F. Marcheselli, K. Giuliodori, V. Consales, E. Molinelli, F. Prattichizzo, M. R. Rippo, A. Campanati, A.D. Procopio, F. Olivieri, A.M. Offidani, MiR‐146a‐5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor‐alpha inhibitor adalimumab, British Journal of Dermatology, Volume 179, Issue 3, 1 September 2018, Pages 787–789, https://doi.org/10.1111/bjd.16659
- Share Icon Share
Extract
Funding sources: this work was supported in part by grants from Fondazione Veronesi, and by grants from the Università Politecnica delle Marche to F.O. and A.D.P.
Conflicts of interest: none to declare.
F.O. and A.M.O. contributed equally to this work.
Dear Editor, Interindividual variability in clinical efficacy of different biological treatments in patients with psoriasis has been observed.1 Thus, the identification of a blood‐based biomarker able to foresee the therapeutic response to treatment is urgently needed, especially considering the high cost of biological therapies.2
Deregulation of microRNAs (miRs) has been previously observed in patients with psoriasis,3 and increasing evidence has highlighted that miRs could be novel biomarkers not only with diagnostic and/or prognostic relevance, but also for monitoring therapeutic response in individuals with psoriasis.4 The aim of this report is to evaluate the association between levels of blood‐based angio‐miRs (miR‐92a, miR‐126‐3p, miR‐221, miR‐222) and inflamma‐miRs (miR‐21‐5p, miR‐146a‐5p) in patients with psoriasis and therapeutic response, measured using Psoriasis Area and Severity Index (PASI) reduction, after treatment with adalimumab.